Gerald L. Ray & Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Gerald L. Ray & Associates’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$998K	Hold	10,725	–	–	0.12%	156
2017 Q2	$974K	Hold	10,725	–	–	0.13%	157
2017 Q1	$941K	Buy	10,725 +500	+5%	+$44.5K	0.13%	151
2016 Q4	$847K	Buy	10,225 +784	+8%	+$67.4K	0.12%	152
2016 Q3	$873K	Sell	9,441 -484	-5%	-$45.6K	0.13%	145
2016 Q2	$772K	Buy	9,925 +250	+3%	+$21.3K	0.12%	148
2016 Q1	$798K	Sell	9,675 -600	-6%	-$48.8K	0.13%	140
2015 Q4	$1.08M	Hold	10,275	–	–	0.17%	111
2015 Q3	$1.08M	Hold	10,275	–	–	0.18%	109
2015 Q2	$1.41M	Hold	10,275	–	–	0.21%	105
2015 Q1	$1.28M	Hold	10,275	–	–	0.19%	110
2014 Q4	$929K	Hold	10,275	–	–	0.14%	131
2014 Q3	$742K	Sell	10,275 -400	-4%	-$26.3K	0.12%	152
2014 Q2	$664K	Hold	10,675	–	–	0.11%	163
2014 Q1	$728K	Sell	10,675 -100	-0.9%	-$7.37K	0.13%	142
2013 Q4	$758K	Buy	10,775 +700	+7%	+$47.5K	0.14%	136
2013 Q3	$727K	Buy	10,075 +1,975	+24%	+$131K	0.15%	134
2013 Q2	$451K	Buy	+8,100	New	+$505K	0.1%	167

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gerald L. Ray & Associates's BMRN Position: Q3 2017 in Review

Gerald L. Ray & Associates held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2017 at 10,725 shares worth $998K. The position accounts for 0.12% of the portfolio, ranked #156.

Gerald L. Ray & Associates first reported a position in BMRN in Q2 2013 and has held it in 18 quarters since. The position peaked at $1.41M in Q2 2015. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

Gerald L. Ray & Associates held 10,725 shares of BioMarin Pharmaceuticals worth $998K as of Q3 2017.
Gerald L. Ray & Associates left its BioMarin Pharmaceuticals share count unchanged in Q3 2017.
BioMarin Pharmaceuticals made up 0.12% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #156 holding.
Gerald L. Ray & Associates first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 18 quarters since.
Gerald L. Ray & Associates's BioMarin Pharmaceuticals position peaked at $1.41M in Q2 2015.
411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.